
FDA awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA). The second IDE study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic institutions.
Lipogems is FDA cleared for use in general applications in orthopedics, arthroscopy and nine other specialties since 2014. Lipogems has worked closely with FDA to seek a separate FDA clearance for a specific indication in knee OA. While Lipogems pursues the knee OA indication, physicians may continue to use the product for the general indications specified in the existing FDA clearance.
Source: Lipogems
FDA awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA). The second IDE study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic...
FDA awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA). The second IDE study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic institutions.
Lipogems is FDA cleared for use in general applications in orthopedics, arthroscopy and nine other specialties since 2014. Lipogems has worked closely with FDA to seek a separate FDA clearance for a specific indication in knee OA. While Lipogems pursues the knee OA indication, physicians may continue to use the product for the general indications specified in the existing FDA clearance.
Source: Lipogems
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.